{"data":{"issuanceinfo":{"industrycode":"204005","industry":"醫療保健","ipoprice":{"ceiling":"57.800","floor":"49.600"},"ipodate":{"start":"2019-09-12 00:00:00","end":"2019-09-17 00:00:00"},"minimumcapital":"5838.25","subscribed":"3.89","marketcap":"267.41億","H_marketcap":"78.89億","pe":"--","codesrate":"100.00","link":"https://staticpdf.iqdii.com/stockdata/notice/02696/2019/2019091200016_c.pdf","ipopricing":"49.600","resultdate":"2019-09-24 00:00:00","enddate":"2019-09-17 00:00:00","listeddate":"2019-09-25 00:00:00","issuenumber":"6469.54萬","issuenumberhK":"646.96萬","issuenumberother":"5822.58萬","grayprice":"48.50","sponsors":"中國國際金融香港證券有限公司,美林遠東有限公司,招銀國際融資有限公司,復星恒利證券有限公司,花旗環球金融亞洲有限公司","raisemoney":"309630.00萬","use":"1、約1,238.5百萬港元（或所得款項凈額的40.0%）將用于撥付持續進行的核心產品的臨床試驗、監管備案及注冊；\n2、約464.5百萬港元（或所得款項凈額的15.0%）將用于撥付持續進行的其他候選生物類似藥（包括HLX12、HLX11及HLX14）的臨床試驗、監管備案及注冊；\n3、約1,083.7百萬港元（或所得款項凈額的35.0%）將用于撥付持續進行的生物創新藥的臨床試驗、監管備案及注冊以及開發免疫腫瘤聯合療法；\n4、約309.6百萬港元（或所得款項凈額的10.0%）將分配至營運資金及一般企業用途。","shares":100,"leadagent":"中國國際金融香港證券有限公司,美林遠東有限公司,中銀國際亞洲有限公司,瑞士銀行香港分行,招銀國際融資有限公司,復星恒利證券有限公司,花旗環球金融亞洲有限公司,海通國際證券有限公司,尚乘環球市場有限公司,法國巴黎證券(亞洲)有限公司,工銀國際證券有限公司,中泰國際證券有限公司,農銀國際證券有限公司,中國光大證券(香港)有限公司,軟庫中華金融服務有限公司","bookrunners":"中國國際金融香港證券有限公司,美林遠東有限公司,中銀國際亞洲有限公司,瑞士銀行香港分行,招銀國際融資有限公司,復星恒利證券有限公司,花旗環球金融亞洲有限公司,海通國際證券有限公司,尚乘環球市場有限公司,法國巴黎證券(亞洲)有限公司,工銀國際融資有限公司,中泰國際證券有限公司,農銀國際融資有限公司,中國光大證券(香港)有限公司,軟庫中華金融服務有限公司","coordinator":"中國國際金融香港證券有限公司,美林遠東有限公司,中銀國際亞洲有限公司,瑞士銀行香港分行,招銀國際融資有限公司,復星恒利證券有限公司,花旗環球金融亞洲有限公司","firstDayOpen":"47.45","IsEiio":0,"Interestdays":7,"PENote":"按經審核的最近年度公司股東應占溢利和發行后總股本計算；發行價未確定時，按招股價中間價計算；發行價確定后，按招股定價計算。","OverAllotment":"有","StabilizingManager":"中國國際金融香港證券有限公司","code":"E02696","name":"復宏漢霖－Ｂ","fullname":"上海復宏漢霖生物技術股份有限公司"},"institutioninfo":{"principaloffice":"中國上海徐匯區虹梅路1801號凱科國際大廈A座9樓","registrars":"香港中央證券登記有限公司","registrarstel":"(852) 2862 8628","chairman":"陳啟宇","secretary":"郭新軍,梁晶晶","telephone":"(8621)3339 5800","substantialshareholders":"上海復星新藥研究有限公司(49.33%)","principalactivities":"公司是一家中國領先的生物制藥公司，旨在為全球患者提供質高價優的創新藥物。","website":"www.henlius.com"},"managerinfo":[{"managername":"Scott Shi-Kau  Liu","post":"首席執行官、總裁兼執行董事","rankno":1},{"managername":"陳啟宇","post":"主席及非執行董事","rankno":2},{"managername":"吳以芳","post":"非執行董事","rankno":3}],"investorinfo":[{"institutionname":"Al-Rayyan Holding LLC","shareholding":"14,213,700.0","percentage":21.97,"ReleaseDate":"2020-03-25 00:00:00","relatedparty":"卡塔爾投資局","subsidiary":["Qatar Holding LLC","Al-Rayyan Holding LLC"],"InverstorType":"公司"},{"institutionname":"AVICT Global Holdings Limited","shareholding":"4,742,100.0","percentage":7.33,"ReleaseDate":"2020-03-25 00:00:00","relatedparty":"深圳市普泰投資發展有限公司","subsidiary":["AVICT Global Holdings Limited"],"InverstorType":"公司"},{"institutionname":"Henlius Biopharmaceuticals Inc.","shareholding":"1,580,700.0","percentage":2.44,"ReleaseDate":"2020-03-25 00:00:00","relatedparty":"LIU博士","subsidiary":["Henlius Biopharmaceuticals Inc."],"InverstorType":"公司"},{"institutionname":"浙江舒泰神投資有限公司","shareholding":"1,580,700.0","percentage":2.44,"ReleaseDate":"2020-03-25 00:00:00","relatedparty":"舒泰神(北京)生物制藥股份有限公司","subsidiary":["浙江舒泰神投資有限公司"],"InverstorType":"公司"}],"TotalShareholdingPercentage":34.18},"result":1,"Version":"4.5.190802.46408","ElapsedMilliseconds":10}